GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » Debt-to-Revenue

Taiko Pharmaceutical Co (TSE:4574) Debt-to-Revenue : 0.53 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Taiko Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円1,276 Mil. Taiko Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円1,627 Mil. Taiko Pharmaceutical Co's annualized Revenue for the quarter that ended in Mar. 2024 was 円5,508 Mil. Taiko Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.53.


Taiko Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Taiko Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co Debt-to-Revenue Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.01 0.45 0.76

Taiko Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.60 0.39 0.48 0.53

Competitive Comparison of Taiko Pharmaceutical Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiko Pharmaceutical Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Taiko Pharmaceutical Co's Debt-to-Revenue falls into.



Taiko Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Taiko Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1068 + 2741) / 5040
=0.76

Taiko Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1276 + 1627) / 5508
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Taiko Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiko Pharmaceutical Co (TSE:4574) Business Description

Traded in Other Exchanges
N/A
Address
No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co (TSE:4574) Headlines

No Headlines